HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for HORMONE-RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE-RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE-RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets hard-to-treat breast cancers
Disease control Recruiting nowThis study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors and control the disease. About 380 adults with various types of breast cancer (…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug cocktail aims to shrink Hard-to-Treat breast cancer
Disease control Recruiting nowThis early-phase trial is testing a new drug called BGB-21447, which blocks a protein that helps cancer cells survive. It is given together with standard hormone therapy (fulvestrant) and sometimes another targeted drug (BGB-43395). The study involves 120 adults with HR+/HER2- me…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for tough breast cancer: experimental drug EP0062 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called EP0062, alone or with standard treatments, in people with a certain type of advanced breast cancer (AR+/HER2-) that has returned or spread. The main goals are to find the safest dose and see if it helps shrink tumors. About 95 adults a…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Ellipses Pharma • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug XB010 takes on advanced cancers in first human trial
Disease control Recruiting nowThis early study tests an experimental drug called XB010, alone or combined with the immunotherapy pembrolizumab, in people with advanced solid tumors (like lung, breast, or head and neck cancers) that have stopped responding to other treatments. The main goals are to find a safe…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New umbrella study aims to match breast cancer patients with best drug cocktail
Disease control Recruiting nowThis study is testing many different drug combinations in people with metastatic breast cancer that has spread or cannot be removed by surgery. Researchers are looking at which combinations work best for different cancer types, such as triple-negative or hormone receptor-positive…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immune-Boosting cocktail aims to tackle Hard-to-Treat breast cancer
Disease control Recruiting nowThis study tests whether adding two immunotherapy drugs (CDX-1140 and CDX-301) to standard chemotherapy (PLD) is safe and helps control metastatic HER2-negative breast cancer. About 30 people with advanced cancer that has not responded to other treatments will take part. The goal…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can switching drugs outsmart resistant breast cancer?
Disease control Recruiting nowThis study tests whether the drug everolimus can help women with a common type of advanced breast cancer (HR-positive, metastatic) whose cancer has stopped responding to a similar drug called alpelisib. The trial will enroll 19 women and measure how many see their tumors shrink. …
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Sponsor: Tel-Aviv Sourasky Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Promising drug combo aims to control advanced breast cancer when standard therapy fails
Disease control Recruiting nowThis study compares a combination of two drugs (elacestrant and capecitabine) to capecitabine alone in people with advanced estrogen receptor-positive breast cancer that no longer responds to CDK 4/6 inhibitors. About 297 participants will be randomly assigned to one of the two t…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Kristina A. Fanucci • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New Antibody-Drug combo shows promise for Hard-to-Treat breast cancer
Disease control Recruiting nowThis phase II trial is testing a drug called ARX788 in 36 people with HER2-low breast cancer that has spread or cannot be removed. ARX788 is an antibody-drug conjugate that delivers a toxin directly to cancer cells with the HER2 protein. The main goal is to see how many patients'…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Laura Huppert, MD, BA • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New targeted cancer drug STX-478 enters human trials
Disease control Recruiting nowThis study tests a new drug called STX-478 in people with advanced solid tumors that have a specific genetic change (PI3Kα mutation). The trial has two phases: first, it tests STX-478 alone to find safe doses; then, it combines STX-478 with other cancer drugs like fulvestrant or …
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New combo therapy for breast cancer bone metastases enters human testing
Disease control Recruiting nowThis early-stage trial tests the drug abemaciclib (a CDK4/6 inhibitor) given together with targeted radiation for people with metastatic HR+ HER2- breast cancer that has spread to bone. The main goal is to find the safest dose of abemaciclib when combined with radiation. About 28…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for Hard-to-Treat breast cancer: targeted drug trial begins
Disease control Recruiting nowThis early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New combo therapy aims to boost breast cancer treatment before surgery
Disease control Recruiting nowThis study tests whether adding hormone therapy to standard chemotherapy and HER2-targeted therapy improves tumor response before surgery in people with HER2-positive breast cancer. About 30 adults with stage II to III disease will participate. The goal is to see if this combinat…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Legacy Health System • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New Triple-Drug attack shows promise for Hard-to-Treat breast cancer
Disease control Recruiting nowThis study is for people with a type of advanced breast cancer called HR+/HER2-negative. It tests a new drug, VS-6766, combined with two standard drugs (abemaciclib and fulvestrant). The goal is to find the safest dose and see if the combination can shrink tumors or stop them fro…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Adrienne G. Waks • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New study aims to find best Pre-Surgery hormone treatment for men with breast cancer
Disease control Recruiting nowThis study tests different hormone therapies in men with breast cancer before they have surgery. The goal is to see which treatment works best to shrink the tumor. About 60 men with hormone receptor-positive breast cancer will take part.
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Jose Pablo Leone • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Could a 4-Week drug combo shrink breast tumors before surgery?
Disease control Recruiting nowThis phase 2 trial is testing whether the drug elacestrant, given alone or with triptorelin (which temporarily stops ovary hormone production), can slow or shrink hormone-sensitive breast tumors in premenopausal women. About 96 women will take the pills daily for 30 days before t…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could electromagnetic waves help shrink breast tumors before surgery?
Disease control Recruiting nowThis pilot study is testing whether a device called TheraBionic P1, which delivers targeted electromagnetic fields, can affect breast cancer tumors before surgery. About 24 women with early-stage, hormone receptor-positive, HER2-negative breast cancer will use the device three ti…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: NA • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for hard-to-treat breast cancer: immune-boosting drug plus chemo shows promise
Disease control Recruiting nowThis study tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy can help shrink tumors or slow disease in people with advanced HER2-negative breast cancer. About 92 adults whose cancer has worsened after prior treatments will receive the combinat…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Promising drug cocktail aims to stop breast cancer recurrence
Disease control Recruiting nowThis study is for people with a type of breast cancer (hormone receptor-positive, HER2-negative) that has come back in the same area after initial treatment. The goal is to see if adding the drug ribociclib to standard hormone therapy can help prevent the cancer from returning ag…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Oana Danciu • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New Triple-Drug cocktail aims to shrink metastatic breast tumors
Disease control Recruiting nowThis study tests whether a combination of three drugs (anastrozole, fulvestrant, and abemaciclib) can shrink or control tumors in people with a common type of advanced breast cancer (hormone receptor positive, HER2-negative). About 20 participants whose cancer has spread or retur…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Blood test may spare breast cancer patients from chemo
Disease control Recruiting nowThis study tests whether a blood test (ctDNA) can identify women with early-stage, hormone-positive breast cancer who can safely avoid chemotherapy. Instead of chemo, they receive a targeted pill (dalpiciclib) plus hormone therapy before surgery. The goal is to reduce side effect…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Weight-Loss drug tirzepatide tested to boost breast cancer outcomes
Disease control Recruiting nowThis study tests whether tirzepatide, a drug used for weight loss, can help patients with early-stage hormone receptor-positive, HER2-negative breast cancer lose at least 5% of their body weight during adjuvant treatment. The trial will enroll 40 adults and also check safety, sid…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can one targeted drug still work after another fails? new trial aims to find out
Disease control Recruiting nowThis Phase 2 trial is testing whether the drug sacituzumab govitecan (Trodelvy) can shrink tumors in people with a specific type of advanced breast cancer (HR+/HER2 low or ultra low) who have already received another targeted drug called T-DXd. The study will enroll 75 participan…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Reshma L. Mahtani, D.O. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Can routine brain scans catch hidden cancer spread in stage IV breast cancer?
Diagnosis Recruiting nowThis study is testing whether routine brain MRIs can find brain metastases in stage IV breast cancer patients who have no neurological symptoms. Researchers will scan 170 participants at the start and again at 6 months or when their cancer first progresses. The goal is to see how…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Diagnosis
Last updated Jun 27, 2026 12:34 UTC
-
New vaginal suppository aims to ease dryness for breast cancer patients
Symptom relief Recruiting nowThis study tests whether Revaree Plus, a hyaluronic acid vaginal suppository, can improve vaginal dryness in women with hormone-receptor-positive breast cancer. About 60 participants will use the suppository for 8 weeks. Researchers will measure changes in vaginal health using a …
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE4 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Mouthwash may tame chemo side effect in breast and lung cancer
Symptom relief Recruiting nowThis phase 2 trial tests whether a dexamethasone mouthwash can lower the chance of painful mouth sores (stomatitis) caused by the cancer drug datopotamab deruxtecan. About 60 people with advanced breast or lung cancer will use the mouthwash for the first five days of each treatme…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Brown University • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC
-
Immune system secrets may improve breast cancer therapy
Knowledge-focused Recruiting nowThis study aims to understand how the immune system reacts to a common breast cancer treatment combination of letrozole and abemaciclib. Researchers will collect tumor and blood samples from 60 postmenopausal women with hormone receptor-positive breast cancer before and after two…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists investigate why breast cancer beats treatments
Knowledge-focused Recruiting nowThis study aims to understand why some breast cancers become resistant to therapy. Researchers will analyze tumor and blood samples from 320 people with HER2-positive, hormone receptor-positive, or triple-negative breast cancer. The goal is to identify changes in cancer cells tha…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE4 • Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Blood test may spot breast cancer resistance before It's too late
Knowledge-focused Recruiting nowThis study is looking at whether a blood test called DiviTum TKa can predict when hormone-receptor-positive, HER2-negative metastatic breast cancer stops responding to treatment. About 100 participants will give blood samples before and during their standard therapy. The goal is …
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New study questions need for hormone therapy in older breast cancer patients
Knowledge-focused Recruiting nowThis study looks at whether women aged 70 and older with low-risk breast cancer can safely skip hormone therapy after surgery. Current guidelines recommend at least 5 years of hormone therapy, but older patients may face more side effects with less benefit. The trial will compare…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE4 • Sponsor: Ottawa Hospital Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Gut bugs may hold key to cancer drug side effect
Knowledge-focused Recruiting nowThis study explores whether the natural bacteria in your gut affect diarrhea caused by the breast cancer drug abemaciclib. Researchers will compare stool samples from 60 women who get diarrhea with those who don't. No new treatments are given—just observation to learn why some pe…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Sponsor: Hubei Cancer Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Breast cancer drugs linked to blood sugar changes? new study investigates
Knowledge-focused Recruiting nowThis study is looking at how hormone treatments for breast cancer, called aromatase inhibitors and tamoxifen, affect blood sugar control and diabetes risk in postmenopausal women. Researchers will compare blood sugar measures in women taking these drugs to healthy women not on tr…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC